Assistant Professor of Medicine
Principal Investigator of Phase II Consortium/NCI and Cooperative Group Trials
NCI Protocol # 6490. A Phase II Study of FOLFOX6, Bevacizumab, and Cetuximab in Colorectal Cancer.
NCI Protocol # 5941. A Phase II Study of PS-341 alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction (GEJ) or stomach.
NCI Protocol # 6580. A Randomized Phase II Study of Bevacizumab (NSC# 704865) and Gemcitabine in Combination with Either Cetuximab (NSC# 714692) or OSI-774 (NSC# 718781) in Patients with Advanced Pancreatic Cancer.
NCI Protocol # 6254. A Phase II Study of Triapine in Combination with Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder.
NCI Protocol # 6335. A Phase II Study of Single Agent Depsipeptide in Patients with Unresctable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
CALGB 80402. Phase II Trial of LE-SN38 in Patients with Metastatic Colorectal Cancer after Progression on Oxaliplatin.
CALGB 80101. A Phase III Trial of Adjuvant Chemoradiation after Resection of Gastric and Gastroesophageal Adenocarcinoma
ECOG 5204. Intergroup Randomized Phase III Study of Prospective Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.
NSABP-C08. A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon.
Principal Investigator at Weill Cornell Medical College- Industry Sponsored Trials
Astra Zeneca. A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (XelodaTM) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line Gemcitabine Therapy (GemzarTM)
Astra Zeneca. A Phase II, double-blind, placebo controlled, randomized study to assess the efficacy and safety of 2 doses of ZACTIMA (ZD6474) in combination with FOLFIRI vs. FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyrimidine-containing regimen
Astra Zeneca. A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs. pemetrexed (Alimta) in Patients with Non-Small Cell Lung Cancer who have Failed One or Two Prior Chemotherapeutic Regimens
Schering-Plough. A Phase II Study of Temozolomide (SCH 52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter
Millennium Pharmaceuticals, Inc. Protocol #C05005. A Randomized, Non-Comparative, Multicenter, Open-Label, Phase 2 Study of TarcevaTM (erlotinib) Alone and of Tarceva plus VELCADETM (bortezomib) for Injection in Patients with Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Memorial Sloan-Kettering Cancer Center. A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients with Cancer